Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 1 ( 42)  
STUDY PROTOCOL  
A Phase II Study  to Evaluate the Efficacy  of IdeS (IgG endopeptidase) to Desensitize 
Transplant Patients with a Positive Crossmatch Test  
 
 
 
 
Sponsors protocol ID: 15 -HMedIdeS -06 
 
 
Sponsor: Hansa Medical AB, Lund, Sweden 
 IND Number:  128074  
 
 
  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 2 ( 42) Table of content  
 
1. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  ................................................................. 5  
1 IMPORTANT MEDICAL PR OCEDURES  .............................................................................................. 7  
1.1 M EDICAL EMERGENCIES CONTACTS  ............................................................................................................... 7 
1.2 O VERDOSE  .......................................................................................................................................................... 7 
2 INTRODUCTION  ....................................................................................................................................... 7  
2.1 D ISEASE AND PATIENT P OPULATION  ............................................................................................................. 7 
2.2 C URRENT TREATMENT  ..................................................................................................................................... 9 
2.3 I DES ..................................................................................................................................................................... 9 
2.4 I DES CLINICAL STUDIES  ................................................................................................................................. 10 
2.5 S TUDY RATIONALE AND D ISCUSSION ON OVERALL STUDY DESIGN  ......................................................... 11 
2.6 R ISK/BENEFIT AND ETHICAL ASSESSMENT  ................................................................................................  12 
3 STUDY OBJECTIVES  ............................................................................................................................. 13 
3.1 P RIMARY OBJECTIVE  ....................................................................................................................................... 13 
3.2 S ECONDARY OBJECTIVES  ................................................................................................................................  13 
3.3 P RIMARY ENDPOINT  ....................................................................................................................................... 14 
3.4 SECONDARY ENDPOINTS  ................................................................................................................................... 14 
4 STUDY DESIGN  ...................................................................................................................................... 14 
4.1 O VERALL STUDY DESIGN AND FLOWCHARTS  .............................................................................................. 14 
4.2 D ECISION CRITERIA FOR  DOSE ESCALATION , INCLUSION OF LIVING  DONOR TRANSPLANTS A ND 
STUDY TERMINATION  ..................................................................................................................................................... 18 
4.3 D ATA SAF ETY MONITORING BOARD  ............................................................................................................. 18 
5 PATIENT SELECTION CR ITERIA  ...................................................................................................... 19 
5.1 
SCREENING  .......................................................................................................................................................  19 
5.2 I NCLUSION CRITERIA  ...................................................................................................................................... 19 
5.3 E XCLUSION CRITERIA  .....................................................................................................................................  19 
5.4 W ITHDRAWAL CRITERIA  ............................................................................................................................... 20 
5.4.1  Criteria for discontinuation from the study  ......................................................................................20  
5.4.2  Procedures for discontinuation of a patient from the study  ..................................................... 20 
6 STUDY CONDUCT  ................................................................................................................................. 20 
6.1 S TUDY TREATMENT  ........................................................................................................................................ 20 
6.1.1  IdeS  ....................................................................................................................................................................... 20 
6.1.2  Storage and handling  ..................................................................................................................................21  
6.1.3  Drug accountability and compliance check  ......................................................................................21  
6.1.4  Administration of investigational drug  ...............................................................................................22  
6.1.5  Desensitization protocol ............................................................................................................................. 22 
6.1.6  Premedication  ................................................................................................................................................. 22 
6.1.7  Prophylactic antibiotic ................................................................................................................................ 22 
6.1.8  Induction therapy  .......................................................................................................................................... 22 
6.1.9 Immunosuppressing agents  ......................................................................................................................22  
6.1.10  Other concomitant medication  .......................................................................................................... 22 
6.2 S TUDY PROCEDURES DESC RIBED PER VISIT  ................................................................................................ 22 
6.3 S AFETY REPORTING  ........................................................................................................................................ 24 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 3 ( 42) 6.3.1  Definition of adverse events  ......................................................................................................................24  
6.3.2  Definitions of serious adverse event  ...................................................................................................... 25 
6.3.3  Recording of adverse events  ..................................................................................................................... 26 
6.3.4  Variables  ............................................................................................................................................................26  
6.3.5  Adverse events based on signs and symptoms  .................................................................................27  
6.3.6  Adverse Events based on examinations and tests  ...........................................................................27  
6.3.7  Follow -up of unresolved adverse events  ............................................................................................. 28 
6.3.8  Reporting of serious adverse events  .....................................................................................................28  
6.3.9  Reporting of suspected unexpected serious adverse events (SUSARs)  ..................................28  
6.3.10  Procedures in case of pregnancy  ...................................................................................................... 29 
6.4 S TUDY ASSESSMENTS  .....................................................................................................................................  29 
6.4.1  Recording of data  .......................................................................................................................................... 29 
6.4.2  Screening and demography procedures  ............................................................................................. 30 
6.4.3  Patient care after end of study  ................................................................................................................30  
6.5 L ABORATORY EFFICACY A SSESSMENTS AND EVALU ATION OF PRIMARY END POINT  ............................ 30 
6.5.1  Analysis of crossmatch tests ..................................................................................................................... 30 
6.5.2  Determination donor specific antibodies (DSAs) and complement fixation  ......................30  
6.6 C LINICAL SAFETY ASSESSMENTS  .................................................................................................................. 30 
6.6.1  Physical examination  ................................................................................................................................... 30 
6.6.2  Height and weight  ......................................................................................................................................... 31 
6.6.3  ECG  ....................................................................................................................................................................... 31 
6.6.4  Vital signs  .......................................................................................................................................................... 31 
6.6.5  Other safety assessments ............................................................................................................................31  
6.7 L ABORATORY SAFETY ASS ESSMENTS  ...........................................................................................................  31 
6.7.1  Clinical chemistry, hematology, coagulation and virology  ........................................................ 31 
6.7.2  Viral surveillance  ...........................................................................................................................................32  
6.7
.3 Pregnancy test  ................................................................................................................................................32  
6.7.4  Determination of kidney function  .......................................................................................................... 32 
6.8 P HARMACOKINETICS AND PHARMACODYNAMICS  ...................................................................................... 32 
6.8.1  Determination of drug concentration in biological samples  .................................................... 32 
6.8.2  Determination of IgG levels in serum  ................................................................................................... 32 
6.9 A NTI-DRUG ANTIBODY ANALYS IS .................................................................................................................  33 
7 BIOLOGICAL SAMPLING PROCEDURES  ......................................................................................... 33 
7.1 H ANDLING , STORAGE AND DESTRUC TION OF BIOLOGICAL S AMPLES  ...................................................... 33 
7.1.1  Pharmacokinetic, pharmacodynamic and anti -drug antibody samples  ............................. 33 
7.2 C HAIN OF CUSTODY OF BIOLOGICAL SAMPLES  ............................................................................................ 33 
7.3 W ITHDRAWAL OF INFORME D CONSENT FOR DONATE D BIOLOGICAL SAMPLES  ....................................  33 
8 ETHICAL AND REGULATORY REQUIREMENTS  .......................................................................... 34 
8.1 E THICAL CONDUCT OF TH E STUDY  ............................................................................................................... 34 
8.2 P ATIENT DATA PROTECTI ON ......................................................................................................................... 34 
8.3 E THICS AND REGULATORY  REVIEW  .............................................................................................................. 34 
8.4 I NFORMED CONSENT  ...................................................................................................................................... 35 
8.5 C HANGES TO THE PROTOC OL AND INFORMED CONS ENT FORM  ...............................................................  35 
8.6 A UDITS AND INSPECTION S ............................................................................................................................. 35 
8.7 A RCHIVING OF INVESTIGATOR STUDY FILE AND STUDY MASTER FILE .................................................  36 
9 STUDY MANAGEMENT  ........................................................................................................................ 36 
9.1 P RE-STUDY ACTIVITIES  .................................................................................................................................. 36 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 4 ( 42) 9.2 M ONITORING OF THE STU DY ......................................................................................................................... 37 
9.3 S OURCE DATA  ..................................................................................................................................................  37 
9.4 S TUDY AG REEMENTS  ...................................................................................................................................... 37 
9.5 I NSURANCE  ....................................................................................................................................................... 37 
9.6 E ND OF STUDY  ................................................................................................................................................. 37 
10 DATA HANDLING  .................................................................................................................................. 37 
10.1  C ASE REPORT FORMS  ..................................................................................................................................... 37 
10.2  S OURCE DATA  ..................................................................................................................................................  38 
10.3  D ATA MANAGEMENT  ...................................................................................................................................... 38 
11 EVALUATION AND CALCULATION OF PHARMACOKINETIC AND PHARMACODY NAMICS 
VARIABLES ....................................................................................................................................................... 38 
11.1  C ALCULATION OR DERIVATION OF PHARMA COKINETIC VARIABLES  ....................................................... 38 
12 STATISTICAL METHODS AND SAMPLE SIZE  ............................................................................... 38 
12.1  D ESCRIPTION OF ANALYSIS SETS  .................................................................................................................. 38 
12.2  M ETHODS OF STATISTICA L ANALYSES  ......................................................................................................... 39 
12.2.1  General principles  .................................................................................................................................... 39 
12.2.2  Patient characteristics ........................................................................................................................... 39 
12.2.3  Safety and tolerability  ........................................................................................................................... 39 
12.2.4  Efficacy on DSA, CDC CXM and FACS CXM  ....................................................................................39  
12.2.5  Pharmacokinetics  .................................................................................................................................... 40 
12.2.6  Pharmacodynamics  ................................................................................................................................ .40 
12.2.7  Anti -drug antibodies  ...............................................................................................................................40  
12.3  D ETERMINATION OF SAMP LE SIZE  ............................................................................................................... 40 
13 PUBLICATION POLICY  ........................................................................................................................ 40 
13.1 
CLINICAL STUDY REPORT  .............................................................................................................................. 40 
13.2  C ONFIDENTIALITY AND OWNERSHIP OF DATA  .......................................................................................... 40 
13.3  P UBLICATION AND PUBLIC DISCLOSURE  .................................................................................................... 40 
13.3.1  Publication Policy  .................................................................................................................................... 40 
13.3.2  Public Disclosure Policy  ........................................................................................................................ 40 
14 REFERENCES .......................................................................................................................................... 41 
 
Table of  figures  
 
Figure 1. Overall treatment schedule. CXM=crossmatch test, Tx=transplantation.  .......... 15  
 
Table of  tables  
Table 1. Study flow chart: Screening to Day 180 after IdeS infusion...................................... 16  
Table 2.  Study flow chart:0/Pre-dose to 48 h after IdeS infusion. Time-points after dosing (0) 
relates to START of infusion. .................................................................................................. 17  
Table 3. The following safety variables will be contained in the DSMB safety data package  18 
Table 4.  Composition of study drug  ....................................................................................... 21  
Table 5.  Clinical chemistry, hematology, coagulation and virology........................................ 31  
 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 5 ( 42) 1. List of abbreviations and definition of terms  
The following abbreviations and special terms are used in this study protocol.  
Abbreviation or 
special term  Explanation  
ABMR  Antibody mediated rejection  
ADA  Anti -drug antibody  
AE Adverse event  
ALT  Alanine aminotransferase  
APTt  Activated Partial Thromboplastin Time  
AST  Aspartate aminotransferase  
ATG  Anti -thymocyte globulin  
ATGAM  Anti thymocyte globuline derived from horse  
AUC  Area under serum concentration -time curve  
BMI  Body mass index  
BP Blood pressure  
BW Body weight  
CKD  Chronic kidney disease  
CL Clearance of drug from plasma/serum  
Cmax  Maximum serum concentration  
CMV  Cytomegalovirus  
COPD  Chronic obstructive pulmonary disease  
CRF  Case report form (electronic/paper)  
CRO  Contract research organi zation  
CRP  C-reactive protein  
CSR  Clinical study report  
CTCAE  Common toxicity criteria for adverse events  
CV Coefficient of variation  
CXM  Crossmatch test  
DD Deceased donor  
DSMB  Data and safety monitoring board  
DSA  Donor specific antibodies  
EBV  Epstein -Barr virus  
ECG  Electrocardiogram  
FACS  Fluorescence -activated cell sorting  
FAS  
FDA  Full analysis set  
Food and drug administration  
GCP  Good clinical practice  
GODT  Global observatory on donation and transplantation  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 6 ( 42) Abbreviation or 
special term  Explanation  
HIV Human immunodeficiency virus  
HLA  Human leukocyte antigen  
IA Immuno adsorption  
ICF Informed consent form  
ICH International conference on harmoni zation  
IdeS  
IRB Immunoglobulin G -degrading enzyme of Streptococcus pyogenes  
Institutional review board  
IVIg  Intravenous immunoglobulin  
LD Living donor  
MedDRA  Medical dictionary for regulatory activities  
MFI  Mean fluorescen ce intensity  
NOAEL  No observed adverse effect level  
PCR  Polymerase chain reaction  
PD Pharmacodynamics  
PI Principal investigator  
PK Pharmacokinetics  
PK (INR)  Prothrombin complex (internationally normali zed ratio)  
PLEX  Plasma exchange  
PPS Per protocol set  
PRA  Panel reactive antibody  
SA Single antigen  
SAB  Single antigen beads  
SAE  
SAR  Serious adverse event  
Serious adverse reaction   
SAP  Statistical analysis plan  
SOC  System organ class  
SPA  Solid phase immunoassay  
Ss Steady state  
SUSAR  Suspected unexpected serious adverse reaction  
t½ Terminal half -life 
tmax  Time to maximum plasma concentration  
Vz Apparent volume of distribution  
Vss Volume of distribution at steady state  
 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 8 ( 42) identification of a suitable donor.  As many as 15% of the listed patients are highly 
sensitized (calculated PRA ≥80)  and it has been reported that less than 15% of the 
sensitized patients in US are transplanted each year despite high priority on the waitlist 
(Yabu, Pando et al. 2013) . The presence of HLA donor specific antibodies (DSA s) is a direct 
contraindication to transplantation because of the risk of hyper -acute antibody -mediated 
rejection with acute allograft loss. For transplant candidates who have antibodies, which react against a wide range of HLA it can be difficult to find a donor against whom they  
have no antibodies . This is true  both for patients waiting for a deceased donor kidney and 
for those within a paired donation program who have  an available live donor against 
which they have  DSAs. Consequently, sensitized patients have an extended waiting  time 
for transplantation and a U.K. study demonstrated that the waiting time increased from 788 days for patients with no or low grade of sensitization to 2232 days (> 6 years) for highly sensitized patients (Fuggle and Martin 2008) . Along the same line, Yabu et al.  
reported that less than 15% of the highly sensitized patients in the US were transplanted per year, despite high priority  (Yabu, Pando et al. 2013) . 
Data demonstrate that desensitization followed by transplantation of patients with DSA 
is clearly associated with short- and long -term survival benefits compared to staying in 
dialysis  (Montgomery, Lonze et al. 2011, Vo, Petrozzino et al. 2013, Orandi, Garonzik -
Wang et al. 2014,  Orandi, Luo et al. 2016 ). In addition, the patient’s quality of life is 
dramatically increased and there are substantial cost- savings associated with 
desensitization compared to dialysis (Vo, Petrozzino et al. 2013) .  
In a study performed at John Hopkins  Hospital, Baltimore,  over 11 years (Montgomery, 
Lonze et al. 2011)  a total of 211 patients underwent HLA -incompatible live- donor kidney 
transplantation following desensitization, with HLA incompatibility defined as DSA detected by crossmatch test or multiplex assay (Luminex).  In the treatment group, 
Kaplan- Meier estimates  of patient survival were 90.6% at 1 year, 85.7% at 3 years, 80.6% 
at 5 years, and 80.6% at 8 years, as compared with rates of 91.1%, 67.2%, 51.5% and 30.5%, respectively, for patients in dialysis -only group. The rate of ABMR after 
desensitization and transplantation has been reported to be 22%, most of which responded to treatment with plasmapheresis  (Montgomery, Warren et al. 2012, Iyer, 
Jackson et al. 2013) . Among patients in the desensitization group who had positive 
crossmatch es on the complement- dependent cytotoxicity assay  (CDC crossmatch) , 
survival rates were 87.7% at 1 year, 82.0% at 3 years, 78% at 5 years and 78.0% at 8 years, as compared with rates of 92.2%, 67.0%, 49.7% and 27.1%, respectively, in the 
dialysis -only group. Patients were matched comprehensively based on cPRA, age, blood 
group, number of renal replacement, race, sex, and the presence or absence of diabetes.  
Recently, a five- year outcome study in 535 living donor kidney  transplants with a positive 
crossmatch (Orandi, Garonzik -Wang et al. 2014)  was reported. In 102 patients with a 
positive complement dependent crossmatch test the 5 -year survival was 70.7%, which is 
comparable to 78.0% reported by the Johns Hopkins group.  
Although many sensitized patients have been successfully transplanted using current 
desensitization protocols there are patients on the kidney transplant waitlist who have previously undergone desensitization unsuccessfully or in whom effective 
desensitization will be highly unlikely.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 9 ( 42) 2.2 Current treatment  
In o rder to increase the likelihood in finding a suitable allograft and  transplanting the 
highly sensitized patients, there are two main approaches (Morath, Opelz et al. 2012) , 
paired donation or desensitization. These approaches may be combined.   
Paired donation programs offer  opportunities for sensitized patients to receive organs 
from  donors to whom they have little or no DSA, with comparable outcomes to un-
sensitized patients (Bray, Nolen et al. 2006) . While 16% of the registered population in 
the Canadian Blood Services Living Donor Paired Exchange National Registry had PRA 
between 80% and 96%, they accounted for 24% of those transplanted. On the other hand, 
those with cPRA of 97% or greater make up 32% of the Registry population but accounted 
for only 10% of transplants (Cole 2015) . Highly sensitized patients may remain on the 
waiting list for several years.  
Over the past decade, novel desensitization protocols have been developed to enable 
patients with high levels of anti- donor an tibodies to receive a transplant with acceptable 
five-year outcomes (Montgomery, Lonze et al. 2011, Orandi, Garonzik -Wang et al. 2014) . 
There is no standardized or approved protocol for desensitization; however, a few 
protocols have been developed and tested in clinical settings (Vo, Wechsler et al. 2008) . 
All of these protocols use techniques to remove antibodies, either through high -dose 
intravenous immunoglobulin (IVIg) or plasma- exchange (PLEX)/immunoadsorption (IA) 
often combined with low -dose IVIg (Montgomery, Zachary et al. 2000, Vo, Wechsler et al. 
2008) . In addition, some protocols u se rituximab in order to inhibit the synthesis of IgG 
(Vo, Wechsler et al . 2008) . The desensitization protocols are often combined with 
induction therapy using steroids and anti- thymocyte globulin (ATG), anti- CD52 (e.g. 
alemtuzumab) and/or anti- IL2R antibody (e.g. basiliximab or daclizumab) in order to 
prevent acute cellular rejections in high -risk patients. PLEX, IA and IVIg treatments have 
the disadvantage of requiring rigorous planning since they involve repeated treatments 
over a long period of time. Therefore, these treatments are difficult to apply when 
transplanting patients with deceased allografts.  
2.3 IdeS  
Immunoglobulin G -degrading enzyme of Streptococcus pyogenes  (IdeS ) is an IgG specific  
endopeptidase . Cleavage of IgG generates one F(ab’) 2- and one homodimeric Fc -fragment 
and efficiently neutralizes Fc -mediated activities of I gG ( HMed doc. No. 2012- 003 ) (von 
Pawel -Rammingen, Johansson et al. 2002, Wenig, Chatwell et al. 2004, Vincents, von 
Pawel -Rammingen et al. 2004) . IdeS -mediated IgG degradation constitutes a novel 
therapeutic principle for the treatment of IgG -driven human diseases.  
Hansa Medical AB has performed in vitro  studies and clearly demonstrated that IdeS 
effectively cleaves purified IgG as well as IgG in serum from human and rabbit. IdeS is very 
specific in that no  other substrate has been found  In addition, 
IdeS treatment rapidly and substantially cleaved anti- HLA IgG in serum from sensitized 
CKD grade 5 patients in vitro  . The reactivity to individual  HLA -
antigens were reduced below the critical Mean Florescence Intensity (MFI) acceptable for 
transplantation and a positive crossmatch test was turned into negative. IdeS offers a 
unique and powerful approach for removing the impenetrable immunology barrier HLA 
antibodies present and would allow life -saving transplants to patients who are currently 
not eligible for kidney transplantation.  

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 10 ( 42) 2.4 IdeS c linical studies  
A phase I study first in man single ascending dose study  showed 
that IdeS  was safe and well tolerated  The study 
demonstrated that IdeS could be administered  with a favourable safety 
profile. It also showed that IdeS could effectively reduce the levels of plasma IgG and that 
newly s ynthesised IgG was not detectable until  after dosing.  
, IdeS completely cleaved the pool of plasma IgG  
  
  
 The data clearly shows that a single dose of IdeS 
is superior to both plasmapheresis and immunoadsorption with respect to efficiency and rate of plasma IgG reduction.    
 
The adverse events that were reported, none of 
which were reported as serious, were as anticipated from the biological nature of the 
drug.   
 
 
All adverse events were mild or moderate.  
One phase II study was completed at Uppsala University Hospital, Sweden in March 2015. 
The study was a single arm study with ascending doses of IdeS in 8 CKD patients on the 
kidney transplantation waiting list. The patients enrolled were diagnosed with CKD, in dialysis and on the waiting list for a kidney transplant. However, transplantation was not part of the study protocol. The treated patients had antibodies against multiple HLA 
antigens with pre-dose MFIs between 6000 and 25000 as meas ured by SAB (Luminex) 
assay. There were two dose groups, 0.12 and 0.25 mg/kg body weight (BW) given once or twice within 48 hours. The study showed that one or two doses of IdeS at 0.25 mg/kg BW in the majority of the patients resulted in HLA antibody levels, acceptable for 
transplantation, measured as an MFI (LABScreen) less than 1100 within 24 hours from 
dosing. In addition, in all patients having a significant pre- dose panel -reactivity the 
percentage PRA was reduced already one hour after IdeS treatment.  It was also concluded 
that in the majority of patients the CDC  crossmatches were converted to negative already 
one hour after a single dose of IdeS (0.12 or 0.25 mg/kg BW) and the crossmatches remained negative for one week. There were a total of five SAEs reported in the study of which four were classified as probable or possible related to study drug. Three of the SAEs were infections. Two phase II studies using IdeS in sensitized patients prior to transplantation are currently ongoing in Uppsala, Sweden and Los Angeles, US.  
In a p hase II study in patients diagnosed with asymptomatic antibody -mediated 
Thrombotic T hrombocytopenic P urpura (TTP) with low ADAMTS13 activity, safety and  
tolerability were assessed after patients receiving a single intravenous dose of IdeS. A secondary objective was  to investigate IdeS efficacy in significantly increasing 
ADAMTS13 activity and decreasing ADAMTS13 antibody levels . Inclusion was 
prematurely terminated  after inclusion of two patients who both showed signs of serum 
sickness  (further described in section 2.6) .  

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 11 ( 42) 2.5 Study rationale and d iscussion o n overall study design   
This study will include patients on the kidney transplant waitlist who have previously 
undergone desensitization unsuccessfully or in whom effective desensitization will be 
highly unlikely. Patients in whom effective desensitization is highly unlikely are defined as patients who have been accepted into a desensitization program but have not been transplanted within a year despite the opportunity of desensitization and paired 
donation. Consequently, these patients have one of the highest unmet medical needs in 
transplantation today. A randomized controlled study in this patient population is not 
feasible as the potential control treatments have already been tried unsuccessfully or judged as hig hly unlikely to succeed .  
The study will assess IdeS  efficacy and safety in removing DSAs and thereby convert a 
positive crossmatch test to negative. The primary endpoint is conversion of the 
crossmatch test following IdeS therapy and hence the patients may  serve as  their own 
controls. The patients included will have an available deceased or live donor allograft with 
a positive crossmatch test at study entry .  
For these patients  there is no available treatment for a control arm and the study is 
therefore open labeled, single arm. There will be a total of 15- 20 (7-13 with live donors  
and 7 -13 with deceased donors ) patients included in the study . The first 3 patients in this 
study will receive a kidney from a deceased donor. P atients will receive one dose of 0.25 
mg IdeS/kg BW on study day 0 with the possibility of an additional IdeS dose within two 
days . This dosing schedule was used in the completed phase II study in highly and 
moderately sensitized CKD patients described above and was found  to be, effective and 
safe in removing DSAs  However, it is desirable to find a d ose, 
which is effective in all patients after a single dose in order to minimize time to transplantation especially for the deceased donor setting where a short cold ischemic 
time is critical . Therefore, there will be a possibility to escalate the dose to 0.5 mg/kg BW 
after evaluation of safety in the first 3 patients. Patients will receive IVIg on day 7 and 
anti- CD20 on day 9 after IdeS treatment. In addition, induction therapy with ATGAM at 
time of transplantation or anti- CD52  (Campath) on day 4 will be given.  
There is evidence that low dose IVIg, given after DSA reduction with PLEX, suppresses 
endogenous antibody production and prevents DSA rebound. Additionally, after 
transplantation in the context of antibody reduction from plasmapheresis and low dose IVIg or high dose IVIg plus anti- CD20, most patients will experience a durable reduction 
in DSA but not third party HLA antibody . Thus, on about day 7 after IdeS dosing , IgG begins 
to return.  From previous studies it has also been demonstrated that healthy subject s and 
some patients develop antibodies to IdeS at this time and there is no experience from administering a second dose of IdeS with a longer interval than 2 days. The current understanding of antibody depletion and reconstitution suggests that the rebound of DSA will be prevented or blunted by treatment with high dose IVIg given at about day 7 after IdeS treatment. At this point the IdeS activity is expected to be n on-detectable or very low 
and not to affect the pharmacological effects of IVIg. Furthermore, the potential donor 
specific anamnestic response would likewise be reduced or prevented by memory B -cell 
depletion with the anti- CD20 antibody rituximab. With the donor antigens expressed on 
the graft the same phenomenon of donor specific B -cell unresponsiveness may be 
observed that is seen in the majority of patients desensitized with plasmapheresis and low dose IVIg. DSA is expected to remain low, whereas, third party antibody, including vaccine antibodies, will recover to normal levels  (Stegall, Dean et al. 2009) . 

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 12 ( 42) Based on the current knowledge, including experience from completed and ongoing 
clinical studies, it is expected that IdeS will inactivate IgG across all compartments 
allowing a rapid and potent reduction of donor specific antibody (DSA) to a level 
acceptable for transplantation.  
2.6 Risk/benefit and ethical assessment  
Patients included in this study  have both a wide breadth of sensitization and  high 
reactivity to common HLA antigens . Transplantation is not possible using current 
standards for desensitization due to antibodies creating a positive crossmatch test. These patients are so strongly sensitized that even with paired donation it is  highl y unlikely to 
identify a donor with a genotype that would allow desensitization with a reasonable likelihood of success. In addition, some of the patients will have failed on earlier attempts of desensitization. Eligi ble patients will either be on the waitlist for a deceased allograft 
or have an identified live donor. However, in both groups transplantation is not indicated 
due to antibodies creating a positive crossmatch test. Sensitized patients have an 
increased risk of ABMR associated with negative long -term graft outcome. From previous 
studies it is known that the ABMR frequency in the highly sensitized patient population is between 25 -39% after desensitization (Abu Jawdeh, Cuffy et al. 2014) . There are 
currently no approved treatments for ABMR but in the event of ABMR the patient will be 
treated according to best clinical practice. This may include plas mapheresis, IVIg, 
complement inhibitors and  anti- CD20 antibodies.  The risk for ABMR and graf t loss  should 
be weighed  against the morbidities, low quality of life and increased mortality associated 
with long term dialysis.  Data demonstrate that transplantation following desensitization 
is clearly associated with short- and long -term survival benefits compared to  staying in 
dialysis (Montgomery, Lonze et al. 2011, Vo, Petrozzino et al. 2013, Orandi, Garonzik -
Wang et al. 2014,  Orandi, Luo et al. 2016 ). In addition, the patient’s quality of life is 
dramatically increased after successful transplantation and there are substantial cost-savings associated with desensitization and subsequent transplantation compared to 
long -term dialysis (Vo, Petrozzino et al. 2013) .  
The patients included in the study will receive premedication with glucocorticoids 
(methylprednisolone) and antihistamines ( lorat adine) before each IdeS infusion in order 
to minimise the risk of infusion reactions. Patients with live donors will be screened for anti- IdeS IgE antibodies as part of the eligibility criteria and if positive they will not be 
included. Patients and healthy subjects who have been previous ly treated have formed 
antibodies to IdeS that persist for some months and then decline, the importance of which 
if unknown. In addition mild and reversible proteinuria has been detected in healthy subjects treated with IdeS.  
It has been demonstrated that IdeS at therapeutic levels can cleave antibody -based drugs 
and IVIG, which are administered as part of treatment of transplant patients in this study. These therapies are administered at appropriate intervals after IdeS therapy in which the 
plasma level of IdeS is expected to have minimal or no effect on these drugs.  
Since IdeS effectively removes the IgG pool, there may be an increased risk of infection. In 
orde r to minimise the risk for bacterial infections all patients treated with IdeS will 
receive prophylactic antibiotics until IgG levels are back to acceptable levels.  Patients will 
be screened for viruses (Hepatitis B, C and HIV, CMV, EBV and BKV) and on- going 
infections and patients having clinical signs of on- going infections at the time of 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 13 ( 42) enrolment will not be included in the study. Patients will be hospitalised for at least 7 days 
and closely monitored for infections and after that instructed to contact the principal 
investigator immediately if they have any sign of infection. There will be a physician specialized  in infectious diseases available for medical advice in case of a patient showing 
signs of infection. In case of infection in a patient with low  IgG plasma levels, intravenous 
immunoglobulin may be indicated.  
The dose s of 0.25 mg/kg and 0.5 mg/kg BW are  well covered by the NOAEL  
 patients in the completed phase II study in 
Sweden were exposed to a total dose of 0.5 mg/kg BW.   
 
   
 
For this patient category the risk/possibility of becoming pregnant is extremely small due to their disease state. However, as an extra safety measure, the requirement for highly effective contraception is part of the inclusion criteria for this study.  A pregnancy test will 
be done at screening and pre -dose IdeS for all women of childbearing potential.   
Patients will be closely monitored for all adverse events and the second dose will only be given if the investigator considers it safe after evaluating adverse events and over  all 
patient status after the first IdeS dose. The principal investigator must make sure that sufficient facilities and procedures are available to handle emergency situations during 
the study. The study sites have extended experience in phase I/II studies  within 
transplantation and graft rejection treatment as well as handling biological drugs. The 
sites have adequate procedures in place to handle unexpected adverse reactions.  
As described above in section 2.4 a p hase II study in asymptomatic TTP patients, 
enrollment was stopped after two subjects show ing signs of serum sickness.  Previously, 
27 patients without concomitant immunosuppression medications have been treated 
with IdeS and none of them showed signs of serum sickness. The sponsor cannot rule out that the underlying d isease was a factor in the development of serum sickness in these 
two subjects. Based on all available safety information from non- clinical and clinical 
studies, the overall benefit/risk pr ofile of IdeS still appears favorable.  
3 Study objectives  
3.1 Primary objective  
• To assess the IdeS efficacy in creating a negative crossmatch test 
3.2 Secondary objectives  
• To determine DSA levels at multiple times (pre- dose, 2, 6 , 24 and 48 hours and days 7, 
14, 21, 28,  64, 90, 120 and 180) post IdeS treatment 
• To determine time to creating a negative CDC crossmatch test 

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 14 ( 42) • To determine time to creating a negative FACS crossmatch test 
• To evaluate safety parameters ( adverse  events, clinical laboratory tests, vital signs and 
ECGs) following IdeS treatment up to day 180  
• To monitor k idney function after IdeS treatment as assessed by, filtration (eGFR), 
creatinine and proteinuria 
• To establish   the pharmacokinetic (PK) profile of  IdeS  
• To establish  the Pharmacodynamic (PD) profile of IdeS (cleavage and recovery of 
IgG)  
• To establish  the immunogenicity profile of IdeS  (ADA)  
3.3 Primary endpoint  
• Efficacy defined as IdeS ability to create a negative crossmatch test within 24 hours 
after IdeS dosing  
3.4 Secondary endpoints  
• DSA levels at pre- dose and 2, 6 , 24 and 48  hours and days 7, 14, 21, 28, 64, 90,  120 and 
180 post IdeS treatment 
• Time to creating a negative CDC crossmatch test 
• Time to creating a negative FACS crossmatch test 
• Safety parameters ( adverse events, clinical laboratory tests, vital signs and ECGs)  
• Kidney function after IdeS treatment assessed by, filtration (eGFR), creatinine and proteinuria up to 180 days  post treatment  
• Pharmacokinetic (PK) profile of IdeS  up to day 14 
• Pharmacodynamic (PD) profile of IdeS (cleavage and recovery of IgG)  up to day 180 
post IdeS  
• Immunogenicity profile of IdeS by measuring anti- drug antibodies  (ADA)  
4 Study design  
4.1 Overall study design and flowcharts  
This is a phase II, open label exploratory study t o assess the IdeS efficacy in creating a 
negative crossmatch  test ( CXM) in a total of 15- 20 p atients (7 -13 with living donors and 
7-13 with a deceased donor) who exhibit DSAs and have a positive crossmatch  test to 
their available live or deceased donors. The first 3 patients in this study will receive a 
kidney from a deceased donor. The study will primarily examine the efficacy of IdeS  in 
creating a negative CXM in these patients. Included patients will be treated with IdeS o n 
day 0 . If it is considered safe and the desired effect is not achieved (negative crossmatch)  
a second dose can be given within 2 days of the first infusion. In addition to IdeS patients 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 15 ( 42) will be given high dose IVIg ( 2 g/kg BW, maximum of 140 g)  on day 7 and anti CD20  
(Rituxima b) on day 9 as outlined in Figure 1 . DSA levels will be monitored 2, 6 , 24 and 48  
hours and 7, 14, 21, 28, 64, 90, 120 and 180 days after  the last IdeS dosing. Safety, 
including kidney function will be monitored at multiple time points up to 180 days  after 
treatment. Pharmacokinetics, pharmacodynamics and anti- drug antibodies will be 
followed. For details on assessments see flow chart in Table 1. Patients who are not 
eligible for transplantation after IdeS treatment will not be transplanted and thus will not 
receive any induction therapy or immunosuppression. All patients who receive IdeS will also be asked to remain in the study and be followed up according to the study protocol 
even if they are not transplanted. In addition, patients who lose their graft during the 
course of the study will remain in the study and be followed up according to the study protocol.  
 
 
Figure 1. Overall treatment schedule. CXM=crossmatch test, Tx=transplantation.   
 
  

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 18 ( 42)  
4.2 Decision criteria for dose escalation , inclusion of living donor 
transplants  and study termination  
The first three patients enrolled in the study will receive a kidney from a deceased donor. 
The s tarting dose in this study is 0.25 mg/kg BW given once or twice, with the possibility 
of a higher dose group of less than or equal to 0.5 mg/kg BW. The decision to escalate the 
dose and to include living donor transplants will be done after evaluation of the efficacy 
and safety. Efficacy will be evaluated with regards to IdeS’ ability to create a negative crossmatch  test in the first three patients  within a timeframe suitable for transplantation. 
If a single dose of IdeS fails to produce a negative crossmatch in any of these patients a 
dose escalation will be justified based on efficacy. Before proceeding to the next dose 
group, a d ata and safety monitoring board  (DSMB ) will review available safety and 
tolerability data (see Table 3 ). Safety data collected up to and including the day 28 visit 
for the first three patients  will be evaluated. The safety data will be compiled to a DSMB  
package and sent to all DSMB  members before the DSMB  meeting. The DSMB package and 
recommendation will  also be sent to FDA before proceeding to a higher dose level  and the 
inclusi on of living donor transplants .  
 In addition, the DSMB will continuously monitor the study safety throughout 
the study. If an unacceptable number of serious side effects or graft losses are observe d 
the DSMB can recommend premature termination of the study.  
Table 3. The following safety variables will be contained in the D SMB  safety data package  
Clinical chemistry  Coagulation  Clinical  safety data  
P-IgG PK (INR)  
 Adverse events  
P-ALP  P-APT T Vital signs  
P-ALT   eGFR  
P-AST    
P-Bilirubin, total   Hematology  Urine  
P-Glucose  B-Hemoglo bin Protein  electrophoresis  
P-Sodium     
 
 B-Differentia l analysis of leucocytes  Protein spot  
 P-CRP  B-Thrombocytes   
P-Albumin     
P-Urea    
P-Triglycerides    
P-Creatinine    
P-Creatinine 
phosphokinase    
4.3 Data safety monitoring board  
The Data and Safety Monitoring Board (DSMB) will monitor participant safety, data quality and evaluate the progress of the study. The constitution, activities and reports of the DSMB shall be governed by the FDA’s “Guidance for Clinical Study  Sponsors: 
Establishment and Operation of Clinical Study  Data Monitoring Committees ” (detailed in 
a study specific DSMB charter ). Both documents will be distributed to all DSMB members. 

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 19 ( 42) The DSMB  will be an external group of experts, independent of the sponsor and consist of 
at least three physicians of which one will be the DSMB  chairman.   
5 Patient selection criteria  
5.1 Screening  
To be eligible for the study patients have to meet all inclusion criteria and no exclusion 
criteria. If the patient has been screened and meets all inclusion and no exclusion criteria and does not receive the dose within 28 days, for reasons such as the patient did not receive an organ offer within the time frame etc., the patient may be rescreened.  No other 
rescreening is allowed.  The re -screening procedure will be the same as the previous 
screening visit with the exception for the virology tests which do not have to be repeated 
if not more than 6 months old. Medical history and concomitant medication will be updated if applicable. Re- screened patients will keep the original  screening number. 
5.2 Inclusion criteria   
1. Male or female age 18 -70 years at the time of screening  
2. Patients on the kidney transplant waitlist who have previously undergone 
desensitization unsuccessfully or in whom effective desensitization will be 
highly unlikely. The breadth and strength of sensitization will predict an 
extremely low likelihood of successful desensitization or kidney paired 
donation.   
3. Patients with a live or deceased donor with a positive crossmatch test.  
4. Patient  must be able to understand and sign the informed consent.  
5.3 Exclusion criteria  
1. Previous treatment with IdeS  
2. Previous high dose IVIg treatment (2 g/kg BW) within 28 days prior to IdeS 
treatment. 
3. Lactating or pregnant females  
4. Women of child -bearing age who are not willing or able to practice FDA -
approved forms of contraception.  
5. HIV- positive patients 
6. Patients with clinical signs of HBV or  HCV infection  
7. Patients with active tuberc ulosis  
8. A significantly abnormal general serum screening lab result according to the 
investigator’s judgement.  Hgb cannot be < 6.0 g/dL . Laboratory safety results 
from within 3 days before screening can be used  
9. Severe other conditions requiring treatment and close monitoring, e.g. cardiac failure > NYHA (New York Heart Association) grade 3, unstable coronary 
disease or oxygen dependent COPD  
10. Individuals deemed unable to comply with the protocol  
11. Patients with clinical signs of  CMV or EBV infection  
12. Patients with a history of major  thrombotic events , patients with active 
peripheral vascular disease or patients with proven  hypercoagulable 
conditions 
13. Patients should not have received investigational drugs within 4 half -lives (or 
similar)  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 20 ( 42) 14. Known allergy/sensitivity to IdeS infusions  
15. Patients who have a live donor and test positive for ImmunoC AP anti- IdeS IgE  
 
5.4 Withdrawal criteria 
5.4.1 Criteria for discontinuation from the study  
Patients may be discontinued from study treatment and assessments at any time. The 
patient is free to discontinue his/her participation in the study at any time and for any 
reason, without prejudice to further treatment. If a patient is withdrawn from the study by the investigator due to adverse events he/she will not be replaced. Patients who 
withdraw for reasons other than adverse events may be replaced.  
The study may be stopped prematurely if:  
1. DSMB recommend that the study should be terminated  
2. Findings that, at the discretion of Principal Investigator(s) and/or Sponsor, 
indicate that further dosing should be stopped  
5.4.2 Procedures for discontinuation of a patient from the study  
A patient who discontinues  after study drug administration will always be asked about 
the reason(s) for discontinuation and the presence of any adverse events. If possible, he/she will be seen and assessed by an investigator(s). Adverse events will be followed. If possible, patients who discontinue from the study before completion should undergo 
the assessments and procedures scheduled for the end of study follow up visit. Patients 
who, for a medical reason, cannot comply with the protocol procedures will be followed by best procedure to retrieve safety and efficacy data.  
If the study is prematurely terminated, the Sponsor will promptly inform the investigators 
and the regulatory authorities of the termination and the reason(s) for the termination. 
The IRBs/IECs will also be promptly  informed and provided the reason(s) for the 
termination either by Sponsor or investigators, depending on local requirements. All patients, those in the study at the time for termination as well as those that have 
completed the study, will be informed about the study termination and the reason(s) for 
it by their respective investigator.  
6 Study conduct  
6.1 Study treatment  
6.1.1 IdeS  
IdeS is a clear colorless liquid. It is formulated at 10 g/L in PBS and intended for 
intravenous administration after dilution. Refer to Table 4  for composition.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 22 ( 42) 6.1.4 Administration o f investigational drug  
Intravenous IdeS will be administered over at least 15 minutes. The first 3 patients will 
receive one dose of 0.25 mg/kg BW IdeS on study day 0 . If it is considered safe and the 
desired effect is not achieved (negative crossmatch test) after the first dose, an additional 
IdeS  infusion can be given within 2 days of the first infusion. The dose schedule may be 
increased to 0.5 mg/kg BW given once or twice after the first 3 patients have been tested . 
The decision to escalate the dose will be done after evaluation of safety and ef ficacy as 
described in section 4.2. 
6.1.5 Desensitization protocol  
In addition to treatment with IdeS, patients will be treated with  high dose IVIg 10% 
solution 2  g/kg BW (max 140g for >70kg) 7 days  after IdeS treatment and 1 g rituximab 
(anti- CD20) 9 (-11) days after IdeS treatment. If deemed necessary by the investigator the 
IVIg dose may be split into two doses administered over days 6 -8. 
6.1.6 Premedication  
Patients will receive premedication with glucocorticoids (methylprednisolone , 250 mg 
intravenously) and antihistamines (lorata dine 10 mg orally or an equipotent 
antihistamine) before each IdeS infusion.  6.1.7 Prophylactic antibiotic  
All patients will receive prophylactic antibiotics or sulpha according to clinical practice at 
each site from the start of IdeS treatment until serum IgG level is back within normal 
range.  
6.1.8 Induction therapy  
Induction therapy can be used if indicated. Si tes are allowed to use either  ATGAM  (anti 
thymocyte globuline derived from horse) or Alemtuzumab (anti- CD52 antibody). Rabbit 
ATG cannot be used since it is efficiently cleaved by IdeS. Alemtuzumab can be given 4 
days after IdeS at the earliest, based on limited experience. If alemtuzumab is used as 
induction therapy  on day 4, pulse steroid treatment can be used up to day 4 to prevent T-
cell mediated rejection.  
6.1.9 Immunosuppressing agents  
Patients will be treated with immunosuppressing agents according to clinical practice at each study center.   
6.1.10  Other concomitant medication  
Supportive therapy considered necessary for the patient’s welfare may be given at the discretion of the investigator. All concomitant medication, including premedication and 
prophylactic antibiotics must be recorded on the concomitant medication page in the CRF.  
6.2 Study procedures described per visit  
Visit 1 (Screening day - 28 to day 0)  
At the screening visit each subject will be informed about the study and after signing the informed consent form assessments for eligibility will commence. Eligibility evaluation, 
collection of concomitant medication, demographic data ( age, sex, race, height, weight and 
BMI ) and medical and surgical history  is performed. A full physical examination, height 
and weight measurements, vital signs including resting blood pressure, pulse, respiratory 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 23 ( 42) frequency, 12- lead resting ECG and body temperature is done. Additionally blood 
sampling for serology (HIV, hepatitis, BK, EBV and CMV), pregnancy  test and clinical 
chemistry, hematology as w ell as blood samples for analysis of DSAs, CDC - and FACS -CXM 
and anti- IdeS IgE antibody analysis (ImmunoC AP) will be collected.  
Visit 2 (d ays 0 -2) 
Patients found eligible at the screening visit will be included in the study. At visit 2 the 
eligibility check will be repeated  within 60 min from IdeS dosing . A pregnancy test will 
be taken. If a female patient has been hospitalized between screening visit and visit 2 , a 
pregnancy test at screening visit will suffice and a pregnancy test at visit 2 is not 
required .  In addi tion methylprednisolone and l orat adine will be administered predose 
to prevent infusion reactions . Vital signs, body temperature, safety lab oratory s ampling , 
pharmacokinetic and pharmacodynamics sampling will be performed  pre -dose, 2 h, 6 h, 
24 h and 48 h post IdeS infusion. In addition blood sampling for DSAs  will be drawn at 
pre-dose,  2 h, 6 h, 24 and 48 h . Blood sampling for CDC - and FACS -CXM will b e done at 
pre-dose,  2 h, 6 h, and 24 h. Any effort should be made to obtain crossmatch test for all 
time- points indicated in the study flowcharts. If this is not possible due to logistics on 
specific sites, the sponsor can allow a smaller number of time- points to be evaluated. 
However, as a minimum one crossmatch test pre- dose and one post- dose IdeS must be 
performed to allow evaluation of the primary endpoint. ADA will be sampled at pre -dose 
and 48 h post IdeS infusion. P- creatinine will be measured at 24 h and 48 h post IdeS 
infusion and eGFR will be calculated . Repeat 24 hour urine collection s will be performed 
day 1 -9 for urine protein elec trophoresis analysis.  AEs and concomitant medication will 
be recorded in the CRF throughout the visit.  AEs that occur in the time period prior to 
administration of the study drug should be recorded as part of the patient’s medical 
history but will not be considered a treatment emergent adverse event (TEAE) unless directly related to study procedures (e.g. hematoma secondary to laboratory testing) or 
it meets the definition of an SAE.  A kidney biopsy on the donor kidney will be performed 
in deceased donor patients.  
Visit 3  (day 3 -6) 
Twenty -four - (24) -hour urine collections will be performed daily, day 1-9, f or urine 
protein electrophoresis analysis . AE and concomitant medication will be assessed.  PK will 
be drawn at 96 hours ±4h.  
Visit 4  (day 7)  
At visit 4 high dose IVIg (2 g/kg BW) will be administered. Prior to IVIg dosing the 
following assessments are made: vital signs, blood sampling for analysis DSAs, 
safetylaboratory parameters, PK, PD, ADA and P- creatinine . The eGFR will be calculated. 
Additional samples for PD and ADA will be drawn after the IVIg infusion. If the IVIg dose 
is split into two doses given over two days the sampling will be performed before and after the first dosing. Repeat 24 hour urine collections will be performed day 1 -9 for urine 
protein electrophoresis analysis. AE and concomitant medication will be assessed.  
Visit 5  (Day 9)  
At visit 5 the patient will be dosed with rituximab. In addition a blood sample for PK and 
PD analysis will be drawn. Repeat 24 hour urine collections will be performed day 1 -9 for 
urine protein electrophoresis analysis. AE and concomitant medication will be assessed.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 24 ( 42) Visit 6  (day 14)  
At visit 6 the patient will be assessed for body weight, AEs and concomitant medication. 
Blood sampling for analysis of DSAs, safety laboratory tests, P- creatinine/eGFR, PK, PD, 
ADA and virus screen for BK, EBV and CMV  will be drawn . Urine will be obtained for 
analysis of proteinuria.  
Visit 7  (day 21)  
Blood sampling for assessment of DSAs, safety laboratory parameters, PD, ADA and P-
creatinine/eGFR will be drawn. In addition AEs and concomitant medication will be assessed. Visits 8 and 9  (day 28 and 64)  
At visits 8 and 9 the patient will be assessed for AEs and concomitant medication. Blood 
sampling for analysis of DSAs, safety laboratory tests, PD, ADA, P- creatinine/eGFR and 
virus screen for BK, EBV and CMV. Urine will be obtained  for assessment of proteinuria. 
At visit 8 vital signs will also be assessed.  
Visits 10 and 11  (day 90 and 120)  
At visits 10 and 1 1 the patient will be assessed for vital signs, AEs and concomitant 
medication. Blood sampling for analysis of DSAs, safety laboratory tests, ADA and P-creatinine/eGFR. At visit 9 a blood sample for virus screen (BK, EBV and CMV) will also be drawn. Urine will be obtained for assessment of proteinuria.  
Visit 12  (day 180, e nd of study ) 
A follow -up visit will be performed 180 +/ - 14 days following IdeS infusion. This will be 
considered the end of study  for the patient. At this visit the patient will be assessed for 
vital signs, ECG, AEs and concomitant medication. Blood sampling for analysis of DSAs, 
pregnancy test, safety laboratory tests, P- creatinine/eGFR , PD and ADA will be 
performed  and e GFR calcu lated. Urine will be obtained for assessment of proteinuria 
and a physical examination will be performed . A kidney biopsy will be performed to 
assess kidney status.  
 
6.3 Safety  reporting  
It is of the utmost importance that all staff involved in the study is familiar with the 
content of this section. The principal investigator is responsible for ensuring this.  
6.3.1 Definition of adverse events  
An adverse event (AE) is the development of an undesirable medical condition or the 
deterioration of a pre- existing medical condition following or during exposure to a 
pharmaceutical product, whether or not considered causally related to the product. 
Relationship to the study drug will be deemed as not related, unlikely, possible or probable.  An undesirable medical condition can be symptoms (e.g. nausea and chest pain), 
signs (e.g. tachycardia and enlarged liver) or the abnormal results of an investigation (e.g. laboratory findings and electrocardiogram s).  
In cases of surgical or diagnostic procedures, the condition/illness leading to such a procedure is considered as the AE rather than the procedure itself.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 25 ( 42) In case of fatality, the cause of death is considered as the AE, and the death is considered 
as its outcome.  
Pre-treatment adverse event:  
A pre -treatment adverse event is any untoward medical occurrence arising or observed 
between signing of informed consent and the first administration of the IMP.  
Treatment emergent adverse event:  
A treatment emergent adverse event is any AE occurring after the administration of the 
IMP and within the time of the follow up period or a pre- treatment adverse event or pre-
existing medical condition that worsens in intensity after administration of the IMP and 
within the time of the follow up period.  
6.3.2 Definitions of serious adverse event  
A serious adverse event (SAE) is an AE  or suspected adverse reaction (SAR) that is 
considered “serious” if, in the view of either the investigator or sponsor, it results in any 
of the following outcomes:   
• Results in death  
• Is immediately life- threatening  
• Requires in- patient hospitalization or prolongation of existing hospitalization. 
Regular dialysis treatment in or outside hospital is not included  
• Hospitalization for transplantation is not considered an SAE  
• Results in persistent or significant disability or incapacity  
• Is a congenital abnormality or birth defect  
• Is an important medical event that may jeopardiz e the patient or may require 
medical intervention to prevent one of the outcomes listed above 
Life -threatening event:  An adverse event or suspected adverse reaction is considered  
“life -threatening” if, in the view of either the investigator or sponsor, its occurrence places 
the patient or subject at immediate risk of death. It does not include an adverse event or suspect ed adverse reaction that, had it occurred in a more severe form, might have caused 
death.  
 
Disability  is defined as a substantial disruption in a person’s ability to conduct normal  
life functions.  
 Hospitalization for inpatient hospitalization or prolongation of existing hospitalization.  
In this study the following will not qualify as an SAE. Elective treatment of a pre- existing  
condition that did not worsen during the clinical investigation is not considered an AE.  
Hospitalization for study drug dosing and observation as required by protocol is not  
considered an SAE. Admittance to an emergency room for observation without being  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 26 ( 42) admitted to the hospital may be considered to be an AE but is not considered as an SAE.  
However, complications that occur during hospitalization are AEs, and if a complication 
prolongs hospitalization, the event is considered serious. Regular dialysis treatment in or outside hospital is not considered an AE or SAE.  
 
Important medical  events that may not result in death, be life- threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical  
judgment, they may jeopardize the patient or subject and may require medical or surgical  
intervention to prevent one of the outcomes listed in this definition. Examples of such  
medical events include allergic bronchospasm requiring intensive treatment in an  
emergency room or at home, blood dys krasias or convulsions that do not result in  
inpatient hospitalization, or the development or drug dependency or drug  abuse.  
 SAEs should be followed until the event resolves, stabilizes, or returns to baseline. If the 
patient is discontinued from the study prior to resolution/stabilization of the SAE, then the patient will be followed as part of the SAE/pharmacovigilance system.  
6.3.3 Recording of adverse events  
In clinical studies, an AE/SAE can occur at any time after signing of the informed consent until the end of the study, including run- in or washout periods, even if no study treatment 
has been administered, e.g. and AE can be related to a procedure in the protocol.  
AEs will therefore be collected on the AE CRF from the time of signing of the informed 
consent and throughout the study period including the follow -up period. However, AEs 
that occur in the time period between informed consent and administration of the trial 
drug should be recorded as part of the patient’s medical history, but will not be considered a treatment emergent adverse event (TEAE) unless directly related to study procedures 
(e.g. hematoma secondary to laboratory testing) or it meets the definition of an SAE.  
6.3.4 Variables  
The following variables will be recorded in the CRF for each AE; description of the AE, the 
date and time (if applicable) when the AE started and stopped, intensity according to Common Toxicity Criteria grade (CTCAE v.4.0 3), seriousness of  the AE, causality rating, 
action taken with regard to investigational product, if AE caused patient to discontinue the study and outcome.   
For each reported AE the investigator will assess a causal assessment of the relationship 
of the event to study procedures and/or IdeS using the following criteria.  
• Unrelated;  applicable to an AE that occurs when the subject was not exposed to 
study treatment or another cause is obvious : 
o The AE does not meet the above criteria 
o There is sufficient information that the etiology of the AE is not related to the study drug  
• Unlikely to be related : applicable to an AE that meets the following criteria:  
o Does not follow a reasonable temporal sequence from dosing of IdeS  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 27 ( 42) o May  readily have been produced by the patient’s clinical state, 
environmental, or toxic factors, or other therapy administered to the 
patient  
• Possibly related:  applicable to AEs where connection with IdeS dosing appears 
unlikely but cannot be ruled out. Applicable to AEs where:  
o It follows a reasonable temporal sequence following dosing of IdeS  
o It follows a known pattern of response to dosing of IdeS (based on animal 
studies)  
• Probably related:  applicable to AEs that are considered, with a high degree of 
certainty, to be related to IdeS. Applicable to AEs where:  
o It follows a reasonable temporal sequence from dosing of IdeS  
o It cannot be reasonably explained by the known characteristics of the 
patient’s clinical state, environmental or toxic factors, or other modes  of 
therapy  
o It follow a known pattern of response to IdeS (based on animal data)  
For SAEs, causal relationship will also be assessed for any study procedure.  
6.3.5 Adverse events based on signs and symptoms  
All AEs spontaneously reported by the patient or reported in response to the open 
question from the study personnel: Have you had any health problems since you were last 
asked? or revealed by observation will be collected and recorded in the CRF. When collecting AEs, the recording of diagnoses is preferred (when possible) rather than recording a list of signs and symptoms  for example: congestive heart failure rather than 
low ejection fraction, rales and dyspnea. However, if a diagnosis is known and there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom  not part of the diagnosis  will be recorded separately, for example: 
congestive heart failure and conjunctivitis . 
6.3.6 Adverse Events based on examinations and tests  
 
If lab oratory  values are judged as clinically significant and/or a treatment has been given 
for a medical event it will be captured as AEs and if SAE criteria is fulfilled they  will also 
be an SAE.  
If vital signs give clinical signs/symptoms and/or require a treatment then they will be 
captured  as AEs and if SAE criteria is fulfilled they will also be SAEs . 
Any new or aggravated clinically relevant abnormal medical finding at a physical 
examination as compared with the baseline assessment will be reported as an AE  and if 
SAE criteria is fulfilled it will also be an SAE . 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 28 ( 42)  
Wherever possible the reporting investigator uses the clinical, rather than the laboratory 
term (e.g. anemia versus  low hemoglobin value).  
6.3.7 Follow -up of unresolved adverse events  
Any AEs that are unresolved at the patient’s last AE assessment in the study are followed up by the investigator until stabilization, for as long as medically indicated  or the overall 
clinical outcome of the patient is known, unless the patient is documented as “lost to follow -up”. All SAEs should be followed until the event resolves, stabilizes, or returns to 
baseline. If the patient is discontinued from the study prior to resolution/stabilization of the SAE, then the patient will be followed as part of the SAE/pharmacovigilance system.   
Reasonable attempts to obtain this information must be made and documented. Sponsor retains the right to request additional information for any patient with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.  
6.3.8 Reporting of serious adverse events  
All SAEs have to be reported, whether or not considered causally related to the 
investigational product, or to the study procedure(s). All SAEs will be recorded in the CRF. 
SAEs will be recorded from the time of admission to the clinic on day 0.   
All Serious Adverse Events (SAE) must be reported, whether or not considered related to the study drug, on a separate SAE Report Form. All SAEs will be recorded in the Case 
Report Form. An assigned CRO will be responsible for reporting all SAEs to regulatory 
authorities and ethics committees in accordance with ICH Good Clinical Practice and local regulations. As soon as the Investigator is aware of a potential SAE he/she should contact the safety CRO appointed by the sponsor by f ax or e -mail and in any case no later than 24 
hours  after the knowledge of such a case. At the time of initial reporting the investigator 
must provide as a minimum requirement, patient number, birth date, nature of the SAE and a preliminary assessment of causality.  
For fatal or life -threatening adverse events where important or relevant information is 
missing, active follow -up is undertaken immediately. Investigators or other site personnel 
inform the sponsor and monitor of any follow -up information on a previously reported 
SAE immediately but no later than within 24 hours of when he or she becomes aware of 
it. The monitor or sponsor will advise the investigator/study site personnel how to proceed.  
The SAE reporting procedures are detailed in the study specific Safety Management Plan. 
This plan is an agreement between the sponsor and . 
6.3.9 Reporting of suspected unexpected serious adverse events (SUSARs)  
A suspected serious adverse reaction is any serious adverse event for which there is a reasonable possibility that the investigational product caused the adverse event. A 
serious adverse reaction is considered "unexpected" if it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed.  
SUSAR MedWatch reports  WILL NOT be filled out for any prolonged hospital admissions 
or readmissions that are related to expected complications of the patients’ primary 

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 29 ( 42) disease (CKD).  For example, prolonged admissions for dialysis or readmission for fluid 
overload as a consequence of CKD since this this is an expected complication of the 
patients’ disease state and not related to study drug. These events will be adjudicated by the PI. Otherwise, all SUSAR MedWatch reports will be submitted to the IRB, study  
sponsor and FDA.  
SUSARs with an outcome of death or are life threatening must be reported to the relevant 
regulatory authorities within 7 calendar days, all other SUSARs must be submitted within 15 calendar days. The SUSAR reporting procedures are detailed in the study specific Safety Management Plan. This plan is an agreement between the sponsor, and  
 will notify the appropriate regulatory agency(ies) of 
any SUSARs on an expedited basis and in accordance with applicable regulations. Sponsor will notify all participating site Investigators.  In addition the sponsor is responsible for informing all investigators in all ongoing studies involving IdeS about all SUSARs.  
It is the responsibility of the site Investigator to promptly notify the IRB and other appropriate institutional regulatory bodies of all unexpected serious adverse reactions involving risk to human subjects as per their applicable requirements.  
6.3.10  Procedures in case of pregnancy  
Pregnancy is an  exclusion criteria and a pregnancy test is performed twice before the study drug 
is infused; at the screening visit and prior to infusion of the IMP. A pregnancy test is also performed at the last study visit.   
If a patient becomes pregnant during the follow up phase of the study, the patient will continue in the study according to study protocol, if possible. A Pregnancy Report Form must be sent by Principal Investigator to sponsor (or designee) at the latest within 24 hours  of learning of the 
pregnancy. The outcome of all pregnancies ( spontaneous miscarriage, elective termination, 
normal birth or congenital abnormality) will be followed up on the Pregnancy Report Form even after the patient has completed or discontinued the study. Sponsor (or designee) wi ll 
follow up on pregnancy outcome 4 weeks after the projected due date.  
Pregnancy itself is not considered an AE or SAE, but any event occurring during pregnancy 
that meets serious criteria must be reported to sponsor and will be handled as a SAE. 
Spontaneous abortions , congenital abnormalities/birth defect s are always considered to be a 
SAE s and will be reported and followed up in accordance with other SAEs. Any SAE occurring 
as a result of a post -study pregnancy and considered reasonably related to the s tudy drug by the 
investigator will be reported to the sponsor (or designee).  
6.4 Study assessments  
6.4.1 Recording of data  
The principal investigator will provide the sponsor with all data produced during the 
study from the scheduled study assessments. He/she ensures the accuracy, completeness, 
legibility, and timeliness of the data reported to sponsor in the CRF and in all required reports. The study assessments are described in the sections below and the timing of 
these assessments are detailed in the study f low charts  (Table 1 and Table 2 ).  It is 
important that PK sampling occurs as close as possible to scheduled time. In order to 
achieve this, other assessments scheduled at the same time may be initiated prior to the time point. Pre- dose assessments may be performed up to 60 minutes prior to dosing.  

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 30 ( 42)  
The timing priority order at a particular time point is:  
1. Blood samples for PK and PD  
2. Samples for DSA, CDC and FACS CXM  
3. Vital signs  
4. Safety laboratory samples  
5. Additional laboratory samples  
Pre-dose assessments may be performed up to 60 minutes prior to dosing.  
6.4.2  Screening and demography procedures  
Each patient will undergo a screening between 28 and 0 days prior to  admission.  
6.4.3  Patient care after end of study  
After study completion, all study patients will be followed up regularly and 
interdisciplinary (by nephrologist and transplant surgeons) according to the center’s follow -up routines for transplanted patients. The frequencies of outpatient visits will be 
adjusted individually to the state of patient health and transplant function.   
6.5 Laboratory efficacy assessments and evaluation of primary endpoin t 
Timing of laboratory efficacy parameters ( CDC and FACS crossmatch tests and DSA 
analysis) is given in the study flow charts 1  and 2  (Table 1 and Table 2 ). The date and time 
of collection will be recorded on the laboratory requ isition form and in the CRF. Samples 
will be labelled, stored and shipped as detailed in the laboratory manual.  
6.5.1  Analysis of cross match tests  
Evaluation of the primary endpoint will be analyzed using the crossmatch test.  CDC and  
flow cytometry (FACS) crossmatch  test will be performed at the time points indicated in 
the study flowcharts  (Table 1 and Table 2 ). 
6.5.2 Determination donor specific antibodies (DSA s) and complement fixation  
Samples for determination of DSAs  will be analyzed in immunoglobulin (Ig) G single 
antigen solid -phase immunoassay (SA -SPA) for antibodies to HLA class I and class II.  The 
assay allows determination of the mean fluorescence intensity (MFI) of antibodies in 
patient serum reacting to an array of individual HLA immobilized to beads. In addition, anti- HLA antibodies with complement fixation ability by detection of C1q will be analyzed 
in a SAB assay . Determination of DSAs  will be performed at a central lab oratory.  
6.6 Clinical safety assessments  
6.6.1  Physical examination  
For timing of individual examinations refer to the study flow chart 1 . A complete physical 
examination will be performed at screening and day 180 and include an assessment of the 
following: general appearance, head and neck, lymph nodes, abdomen, musculo -skeletal, 
cardiovascular, respiratory and gross neurological examination.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 31 ( 42) 6.6.2  Height and weight  
Regarding the timing for assessments of height and weight refer to the study flow charts 
1 and 2  (Table 1 and Table 2 ). Measurements should be taken without shoes. Body mass 
index will be calculated from the height and weight. The timing of individual measurements is indicated in the study flow chart  (Table 1 and Table 2 ). 
6.6.3  ECG  
ECG 12- lead will be taken after 10 minutes rest at screening and on day 180.   
6.6.4  Vital signs  
Vital signs , blood pressure, pulse and respiratory frequency will be measured as outlined 
in the study flow charts 1 and 2  (Table 1 and Table 2 ). At dosing, blood pressure and pulse 
will be recorded pre -dose, 2, 6 , 24 and 48 hours post -dose. In addition, the patients will 
be monitored with oximetry during the infusion and the following 24 hours.  
6.6.5  Other safety assessments  
Body temperature will be measured as specified in the study flow charts at screening and 
study visi t 2 (Table 1 and Table 2 ). At visit 2/dosing, body temperature will be recorded 
pre-dose, 2 , 6, 24 and 48 hours post -dose.  
6.6.6 Kidney b iopsy  
A kidney b iopsy will be performed at visit 2 on deceased donor kidneys and at visit 12 
on living and deceased donor kidneys (Table 1). If standard of care kidney biopsies are 
performed for any reason, e.g. suspected rejections, a de -identified copy of the kidney 
biopsy report will be collected .   
6.7 Laboratory safety assessments  
Timing of laboratory efficacy parameters is given in the study flow charts 1 and 2  (Table 1  
and Table 2 ). The date and time of collection will be recorded on the laboratory 
requisition form and in the CRF. Samples will be labelled, stored and shipped as detailed in the laboratory manual.  
6.7.1  Clini cal c hemistry, h ematology, c oagulation and v irology  
The following blood samples for determination of clinical chemistry, hematology, 
coagulation and total IgG in plasma will be taken:  
Table 5. Clinical chemistry, hematology, coagulation and virology  
P-IgG, total  P-PK(INR)  
P-ALP  P-APTt  
P-ALT  Hematology  
P-AST  B-Hemoglo bin 
P-Bilirubin, total  B-Differential analysis of leucocytes  
P-Glucose  B-Thrombocytes  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 32 ( 42) P-Sodium   
P-CRP  *Virology  
P-Albumin  B-HIV  
P-Urea  B-Hepatitis B surface antigen  
P-Triglycerides  
P-Creatinine  
P-Creatinine 
phosphokinase  B-Hepatitis C antibodies  
 
*Virology samples for HIV and hepatitis will be taken at s creening.  Test results not older 
than 6 months can be used .  
Additional laboratory variables c an be performed if judged appropriate by the 
investigator.  
6.7.2 Viral surveillance  
Samples will be taken in all patients as outlined in the study flow chart for BK -, EBV and 
CMV -PCR for early diagnosis of viral activations/reactivations and early treatment, 
respectively. Extra samples should be taken if indicated.  At screening,  results not older 
than 6 months can be used . 
6.7.3 Pregnancy test  
Serum B -HCG will be determined at screening, pre- dose and on day 180 using validated 
standard methods  
6.7.4 Determination of kidney function  
Evaluation of kidney function will be done based on P- creatinine analysis  and calculation 
of filtration rate (eGFR). P roteinuria tests (spot urine/creatinine) will be performed at the 
time points indicated in the study flowcharts. In addition 24 hour urine collections  for 
electrophoresis analysis of proteins will be performed daily starting after transplantation 
and up to  day 9. The amount of urine per 24 hour will be measured and two samples will 
be taken from the collection. One sample will be analyzed at the hospital laboratory and one sample will be stored and analyzed later if deemed necessary.  
6.8 Pharmacokinetics and pharmacodynamics 
6.8.1  Determination of drug concentration in biological samples  
Samples for determination of IdeS  levels in serum (PK ) will be  performed at the time 
points indicated in the study flowcharts and analy zed by  
  
6.8.2  Determination of IgG levels in serum  
Samples for determination of IgG levels in serum (PD) will be performed at the time points indicated in the study flowcharts and  analy zed by , 

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 33 ( 42) England. Samples will also be qualitatively analyzed by gel electrophoresis for IgG 
integrity by  
6.9 Anti -drug antibody analysis  
Venous blood samples for determination of anti- drug antibodies (ADA) will be taken at 
the times presented in the study flow charts ( Table 1  and Table 2 ) and analyzed by 
. Determination of anti- IdeS IgG 
antibody concentrations in serum will be performed using anti- IdeS ImmunoCAP . At 
screening anti- IdeS  IgE antibodies will be drawn . This will be used for research purpose  
for patients with deceased donors and as part of the eligibility criteria for patients with 
live donors . 
The normal range of anti- IdeS IgG antibodies is <2- 78 mg/L  (HMed Doc. No. 2012 -041) . 
Patients who are not back within the normal ADA range at study completion will be asked 
to come back for a follow up ADA sampling at 12 months. The results from the 12 month s 
ADA samples will be reported separately.  
7 Biological sampling procedures  
7.1 Handling, storage and destruction of biological samples  
Samples will be used or disposed after analyses. A detailed description on sample collection, handling and shipping will be provided in a separate laboratory manual.  
7.1.1  Pharmacokinetic, pharmacodynamic and anti -drug antibody samples  
Samples will be disposed after the clinical study report has been finaliz ed, unless retained . 
 Study samples 
may be stored on behalf of the sponsor for a maximum of four years after completion of 
the stud y report.  
7.2 Chain of custody of biological samples  
A full chain of custody is maintained for all samples throughout their life cycle.  
The principal investigator keeps full traceability of collected biological samples from the 
patients while in storage at the center  until shipment and keeps documentation of receipt 
of arrival.  
The sample receiver keeps full traceability of the samples while in storage and during use until used or disposed.  
Sponsor keeps oversight of the entire life cycle through internal procedures, monitoring 
of study sites and auditing of external laboratory providers.  
7.3 Withdrawal of informed consent for donated biological samples  
If a patient withdraws consent to the use of biological samples donated the samples will 
be disposed/destroyed, if  not already analy zed and documented.  
The principal investigator:  

Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 34 ( 42) • will ensure that patient withdrawal of informed consent is notified immediately to 
sponsor  
• will ensure that biological samples from that patient, if stored at the study site, are immediately  identified, disposed/destructed and the action documented.  
• will ensure the laboratory(ies) holding the samples is/are informed about the withdrawn consent immediately and that samples are disposed/destructed and the action documented returned to the study site.  
In the event that analysis/research has already been performed, sponsor will retain the results and associated data for regulatory reasons but these will not be used in any subsequent analyses.  
8 Ethical and regulatory requirements  
8.1 Ethical conduct of  the study  
The study will be performed in accordance with ethical principles that have their origin 
in the latest Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, 
applicable regulatory requirements.  
8.2 Patient data protection  
The informed consent form (ICF) will incorporate wording that complies with relevant 
data protection and privacy legislation.  
8.3 Ethics and regulatory review  
An ethical review board must approve the final study protocol, including the final version of the ICF and any other written information to be provided to the patients. The investigator will ensure the distribution of these documents to the applicable ethical 
review board, and to the study site staff. The opinion of the ethical review board must be 
given in writing.  
Sponsor must approve any modifications to the ICF that are needed to meet local 
requirements.  
No patient will be enrolled in the study, the final study protocol, and the final version of 
the informed consent form are approved by the national regulatory authority or a notification to the national regulatory authority is done, according to local regulations.  
The distribution of any of these documents to the national regulatory authorities will be 
handled by sponsor.  
Sponsor will provide ethical review boards and principal investigators with safety 
updates/reports according to local requirements.  
Progress reports and notifications of serious and unexpected adverse drug reactions will be provided to the ethical review board according to local regulations and guidelines.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 35 ( 42) 8.4 Informed consent  
The principal investigator(s) at the centers  will: 
• Ensure that the patient is given full and adequate oral and written/read 
information about the nature, purpose, possible risk and benefit of the study.  
• Ensure that the patients are notified that they are free to discontinue the study at any time.  
• Ensure that the patient is given the opportunity to ask questions and allowed time to consider the information provided.  
• Obtain and document the patient’s signed and dated informed consent before conducting any procedure specifically for the study.  
• Ensure the original, signed informed consent form is stored in the Investigator’s Study File.  
• Ensure a copy of the signed informed consent form is given to the patient.  
8.5 Changes to the protocol and informed consent form  
Study procedures will not be changed without the mutual agreement of the principal investigator and sponsor.  
If there are any changes to the study protocol, then these changes will be documented in 
a study protocol amendment.  
The substantial amendment(s) must be submitted to regulatory authorities and approved 
by the ethical review board before implementation. Local requirements must be followed 
for amended protocols  and approval obtained if required . Sponsor will distribute any 
subsequent amendments and new versions of the protocol to the principal investigator.  
If a protocol amendment requires a change to a cente r’s informed consent form, sponsor 
and the center ’s ethical review board must approve the revised informed consent form 
before the revised form is used.  
If local regulations require, any administrative change will be communicated to or 
approv ed by the ethical review board.  
8.6 Audits and inspections  
The investigator(s)/institution will permit study -related monitoring, audits, IRB/IEC 
review, a regulatory inspection(s), providing direct access to source data/documents  and 
give p ermission to examine, analyze, verify, and reproduce any records and reports that 
are important to evaluation of a clinical study . Any party (e.g., domestic and foreign 
regulatory authorities, sponsor´s monitors and auditors) with direct access should take 
all re asonable precautions within the constraints of the applicable regulatory 
requirements(s) to maintain the confidentiality of patients´ identities and sponsor´s proprietary information.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 36 ( 42) Authori zed representatives of sponsor or a regulatory authority may perform audits or  
inspections at the cent er, including source data verification. The purpose of an audit or 
inspection is to systematically and independently examine all study -related activities and 
documents, to determine whether these activities were conducted, and data were 
recorded, analy zed, and accurately reported according to the protocol, Good Clinical 
Practice (GCP), guidelines of the International Conference on Harmoniz ation (ICH), and 
any applicable regulatory requirements. The investigator will contact sponsor immediately if contacted by a regulatory agency about an inspection at the center . 
8.7 Archiving of Investigator Study File and Study Master File  
The investigator is responsible for maintaining all records, which enable the conduct of the study at the site to b e fully understood, in compliance with ICH -GCP. The study documentation 
including all the relevant correspondence should be kept by the investigator for at least 10 years 
after the study report is final. No study documents may be destroyed without prior wr itten 
agreement between the investigator and Hansa Medical AB. Should the investigator elect to 
assign the study documents to another party, or move them to another location, Hansa Medical AB must be notified.  
Hansa Medical AB will archive the Study Master File in accordance with ICG -GCP and 
applicable regulatory requirements.  
9 Study management  
9.1 Pre-study activities  
Before the first patient is entered into the study, it is necessary for a representative of 
sponsor to visit the investigational study site for a site initiation visit to:  
• Determine the adequacy of the facilities to give the sponsor information about 
wheth er the study centre has knowledge, enough time, a sufficient patient pool, 
and sufficient training to manage the study in a good way in terms of patient inclusion, patient handling, data and overall study management.  
• Discuss with the investigator(s) (and other personnel involved with the study) their responsibilities with regard to protocol adherence and the responsibilities of sponsor or its representatives. This will be documented in a site initiation visit 
report and in the clinical study agreement between sponsor and the investigator  
Before the first patient is entered into the study, a sponsor representative will review and discuss the requirements of the clinical study protocol and related documents with the investigational staff and also train them in any study specific procedures and system(s) 
utilised.  
The principal investigator will ensure that appropriate training relevant to the study is 
given to all staff, and that any new information relevant to the performance of this study is forwarded to the staff involved.  
The principal investigator will maintain a record of all individuals involved in the study (medical, nursing and other staff).  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 37 ( 42) 9.2 Monitoring of the study  
During the study, a sponsor representative will have regular contacts with the study site, 
including visits to:  
• Provide information and support to the investigator(s).  
• Confirm that facilities remain acceptable.  
• Confirm that the investigational team is adhering to the protocol, data are being accurately and timely recorded in the CRFs, and investigational product 
accountability checks are being performed.  
• Perform source data verification (a comparison of the data in the CRFs with the 
patient’s medical records at the hospital or practice, and other records relevant to the study) including verification of informed consent of participating patients. This will be done using print outs of records for each patient.  
• Ensure withdrawal of informed consent to the use of the patient’s biological samples is reported and biological samples are identified and  disposed/destructed 
accordingly, and the action is documented, and reported to the patient.  
The sponsor and the CRO will be available between visits if the investigator(s) or other staff at the center  needs information and advice about the study conduct.  
9.3 Source data  
Refer to the source data document for location of source data.  
9.4 Study agreements  
The principal investigator must comply with all the terms, conditions, and obligations of the clinical study agreement for this study. In the event of any inconsistency between this clinical study protocol and the clinical study agreement, the clinical study protocol will 
prevail.  
Agreements between sponsor and the principal investigator must be in place before any 
study -related procedures can take place, or patients  be enrolled.  
9.5 Insurance  
All patients in the study are covered by an insurance held by Hansa Medical AB.  
9.6 End of study  
The end of the study is defined as “the last visit of the last patient”.  
10 Data handling  
10.1 Case Report Forms  
A CRF/eCRF will be provided by a CRO. If an eCRF is chosen the system should be validated in accordance with regulatory and system requirements.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 39 ( 42) The final criteria for the PPS, regarding which protocol deviations that warrant 
exclusions, will be determined when all data on protocol violations/deviations are 
available.  
12.2 Methods of statistical analyses  
12.2.1  General principles  
No formal statistical hypothesis testing will be performed in this study. Data will be presented by actual dose received.  
12.2.2  Patient characteristics  
The following demographic variables will be summarized : age, sex, race, height, weight 
and BMI for all dose groups as appropri ate. 
Medical/surgical histories and medications taken before screening will be listed including 
comments and coded fields.  
Baseline assessments of safety variables (ECG, vital signs, and laboratory parameters) will 
be listed by dose groups as appropriate.  
12.2.3  Safety and tolerability  
All safety and tolerability data will be listed as specified in the SAP.  
Adverse events will be collected for each patient from visit 1  until follow -up. Serious 
adverse events will be recorded from the time when informed consent is obtained (Visit 
1) until the follow -up visit.  
The following summaries of AEs will be given by treatment and in total:  
The number of patients who had any AEs, SAEs, AEs that led to withdrawal, AEs related 
to study drug and AEs with severe intensity . 
If the number of AEs is  sufficiently large, summar ies will be presented by  PT (Preferred 
term) and SOC (System organ class) according to MedDRA vocabulary.  
Severity, time of onset, duration, action taken, concomitant therapy started and patient 
outcome of the AEs will be given in data listings only. AEs which were reason for premature discontinuation of study drug will be listed separately .  
Furthermore, SAEs and AEs that led to withdrawal will be listed separately.  
12.2.4  Efficacy on DSA, CDC CXM and FACS CXM  
CDC  crossmatch results (positive or negative and when applicable titer) before and after IdeS 
treatment will be determined for each patient and presented in listing sorted by treatment, 
patient, and time -point. In addition, time to conversion of c rossmatch will be calculated.  
FACS crossmatch results (positive or negative and when applicable channel shift) before and after IdeS treatment will be determined for each patient and presented in listing sorted by treatment, patient, and time -point. In addition, time to conversion of crossmatch will be 
calculated.  
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 40 ( 42) HLA antibodies including DSA will be measured with SAB assays. Summary statistics of MFI 
values for DSA and for all HLA for each patient will be produced by time point, including min, 10th percentile, median, 90th percentile, and max. In addition, patient listings of MFI values for DSA and all HLA for all patients will be produced. 
12.2.5  Pharmacokinetics  
Pharmacokinetic (PK) variables will be summariz ed using appropriate descriptive 
statistics (e.g.  n, geometric mean, harmonic mean for t
1/2, coefficient of variance (CV), min, 
median, max) by treatment group.  
12.2.6  Pharmacodynamics  
All data associated with the efficacy of IdeS in cleaving IgG will be presented using listings 
for each dose group.  If feasible, the data will be explored graphically.  
12.2.7  Anti -drug antibodies  
All anti- IdeS antibody data will be presented using listings . 
12.3 Determination of sample size  
Sample size is not based on formal statistical considerations. Due to the nature of the primary endpoint of the study it is expected that data from 15- 20 patients should suffice 
to achieve the objectives of the study. Also, the sample size is in line with experience from previous similar Phase II studies with other compounds to obtain adequate safety, 
tolerability and PK data to achieve the objectives of the study.  
13 Publication policy  
13.1 Clinical Study Report  
The results from this study will be reported in a clinical study report (CSR) within one year 
after completion of the last patient. This will be prepared by Hansa Medical AB and submitted for comments and signature to the signatory investigator(s). 
13.2 Confidentiality and Ownership of data  
Any confidential information relating to the IMP or the study, including any data and results 
from the study will be the exclusive property of Hansa Medical AB. The investigator and any 
other persons involved in the trial will protect the confidentiality of the proprietary information belonging to Hansa Medical AB.  
13.3 Publication and Public Disclosure  
13.3.1  Publication Policy  
At the end of the study, one or more manuscripts for joint publication may be prepared in collaboration between the investigator(s) offered authorship and Hansa Medical AB.  
Any external Contract Research Organisation or laboratory involved in the conduct of this  study 
has no publication rights regarding the study. 
13.3.2  Public Disclosure Policy  
The study will be uploaded to the EudraCT database. 
Clinical study protocol  Doc No: 201 7-008 
15-HMedIdeS -06   
Version 5.0, dated 2017-03- 20 
 
Page 42 ( 42) Orandi, B. J., J. M. Garonzik-Wang, A. B. Massie, A. A. Zachary, J. R. Montgomery, K. J. 
Van Arendonk, M. D. Stegall, S. C. Jordan, J. Oberholzer, T. B. Dunn, L. E. Ratner, S. Kapur, R. P. Pelletier, J. P. Roberts, M. L. Melcher, P. Singh, D. L. Sudan, M. P. Posner, J. M. El-Amm, R. Shapiro, M. Cooper, G. S. Lipkowitz, M. A. Rees, C. L. Marsh, B. R. Sankari, D. A. Gerber, P. W. Nelson, J. Wellen, A. Bozorgzadeh, A. O. Gaber, R. A. Montgomery and D. L. Segev (2014). "Quantifying the risk of incompatible kidney transplantation: a multicenter study." Am J Tr ansplant 14(7): 1573-1580. 
Orandi, B. J., X. Luo, A. B. Massie, J. M. Garonzik-Wang, B. E. Lonze, R. Ahmed, K. J. Van Arendonk, M. D. Stegall, S. C. Jordan, J. Oberholzer, T. B. Dunn, L. E. Ratner, S. Kapur, R. P. Pelletier, J. P. Roberts, M. L. Melcher, P. Singh, D. L. Sudan, M. P. Posner, J. M. El- Amm, 
R. Shapiro, M. Cooper, G. S. Lipkowitz, M. A. Rees, C. L. Marsh, B. R. Sankari, D. A. Gerber, P. W. Nelson, J. Wellen, A. Bozorgzadeh, A. O. Gaber, R. A. Montgomery and D. L. Segev (2016). "Survival Benefit  with Kidney Transplants from HLA- Incompatible Live 
Donors." N Engl J Med  374(10): 940-950. 
Stegall, M. D., P. G. Dean and J. Gloor (2009). "Mechanisms of alloantibody production in sensitized renal allograft recipients." Am J Transplant 9(5): 998-1005. 
Wenig, K., L. Chatwell, U. von Pawel-Rammingen, L. Björck, R. Huber and P. Sondermann 
(2004). "Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG." Proc Natl Acad Sci U S A  101(50): 17371-17376. 
Vincents,  B., U. von Pawel-Rammingen, L. Björck and M. Abrahamson (2004). "Enzymatic 
characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding." Biochemistry  43(49): 15540-
15549. 
Vo, A. A., J. Petrozzino, K. Yeung, A. Sinha, J. Kahwaji, A. Peng, R. Villicana, J. Mackowiak and S. C. Jordan (2013). "Efficacy, outcomes, and cost- effectiveness of 
desensitization using IVIG and rituximab." Transplantation 95(6): 852-858. 
Vo, A. A., E. A. Wechsler, J. Wang, A. Peng, M. Toyoda, M. Lukovsky, N. Reinsmoen and S. C. Jordan (2008). "Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab." Am J Trans plant 8(1): 144-
149. 
von Pawel-Rammingen, U., B. P. Johansson and L. Björck (2002). "IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G." EMBO J  
21(7): 1607-1615. 
Yabu, J. M., M. J. Pando, S. Busque and M. L. Melcher (2013). "Desensitization combined with paired exchange leads to successful transplantation in highly sensitized kidney transplant recipients: strategy and report of five cases." Transplant Proc 45(1): 8 2-87.
 
 